Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.74 |
| ▸ | HSP90AB1 | P08238 | 19/20 | 0.74 |
| ▸ | HSP90B1 | P14625 | 5/20 | 0.54 |
| ▸ | TRAP1 | Q12931 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4709172 | 1.00 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5145460 | 0.94 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5145464 | 0.94 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4716608 | 0.90 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5148096 | 0.88 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5148097 | 0.88 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4709365 | 0.86 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL5146989 | 0.86 | HSP90AA1 (0.74) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4706050 | 0.86 | HSP90AB1 (0.75) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1220181 | 0.85 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2007-09-06 | — | — | US | claimed |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-05-26 | — | — | US | disclosed |
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207984-A1 | Cyclohexylamino Benzene, Pyridine, and Pyridazine Derivatives | HRH4, P2RX4, CDK4 | HSP90AA1 3248/4885HSP90AB1 2805/4885HSP90B1 3218/4885 |
| US-20160143884-A1 | USE OF TETRAHYDROINDAZOLYLBENZAMIDE AND TETRAHYDROINDOLYLBENZAMIDE DERIVATIVES FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) | HSP90AB1, HSP90B1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 1/4885HSP90B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.